Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody
The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.
1. A method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associated with COVID-19 comprising administering to a human subject in need thereof an effective amount of an anti-LIGHT antibody comprising a heavy chain and a light chain variable region comprising a CDR-H1 having the sequence of SEQ ID NO: 2, CDR-H2 having the sequence of SEQ ID NO: 3, CDR-H3 having the sequence of SEQ ID NO: 4, CDR-L1 having the sequence of SEQ ID NO: 5, CDR-L2 having the sequence of SEQ ID NO: 6, and CDR-L3 having the sequence of SEQ ID NO: 7.
2. The method of claim 1 , wherein the subject has acute respiratory distress syndrome (ARDS).
3. The method of claim 1 , wherein the subject has acute lung injury (ALI).
4. The method of claim 1 , wherein the subject has pneumonia.
5. The method of claim 1 , wherein administration of the anti-LIGHT antibody reduces serum free-LIGHT levels in the subject.
6. The method of claim 1 , wherein a single dose of about 16 mg/kg of the anti-LIGHT antibody is administered.
7. The method of claim 1 , wherein the subject has received, or is currently receiving, an anti-COVID-19 therapy comprising a corticosteroid, hydroxychloroquine, and/or remdesivir.
8. The method of claim 1 wherein administration of the anti-LIGHT antibody reduces the subject's risk of mortality by equal to or greater than 50% at 28 days and/or 60 days after administration.
9. The method of claim 8 , where the subject is 60 years of age or older.
10. The method of claim 1 , wherein administration of the anti-LIGHT antibody reduces the subject's risk of respiratory failure.